Efficacy of Apixaban in Malignancy With Deep Venous Thrombosis
A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 100 participants.
Also called NCT04462003
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 100 participants
- Sponsor
- Registry
-
NCT04462003
-
- Other papers using this trial's data
- Efficacy and safety of apixaban in patients with active malignancy and acute deep venous thrombosis
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Egypt
- Registry status
- Unknown status
Technical summary
Registry record NCT04462003. Randomized; single masking; primary purpose treatment. Start 2019-07-03 (actual); primary completion 2020-07-02 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy of Apixaban in Malignancy With Deep Venous Thrombosis
- Acronym
- DVT (deep vein thrombosis)
- Condition
- Deep Vein Thrombosis
- Condition
- Malignancy
- Intervention (Drug)
- Apixaban
- Intervention (Drug)
- Enoxaparin
- Lead sponsor
- Beni-Suef University
Record details
- Record id
cardio:ct-nct04462003- Content hash
b90034c0c6b86abab1f633affe971d5711b9e2358aa8255b20d8cfe824fd2de2